Search

Your search keyword '"Farowski F"' showing total 90 results

Search Constraints

Start Over You searched for: Author "Farowski F" Remove constraint Author: "Farowski F"
90 results on '"Farowski F"'

Search Results

3. A quality improvement study on the reduction of central venous catheter-associated bloodstream infections by use of self-disinfecting venous access caps (STERILE)

8. Phänotypisierung der nichtalkoholischen Fettlebererkrankung (NAFLD) durch das intestinale Mikrobiom – Sind wir schon so weit?

9. Kein signifikanter Einfluss des Fruktosekonsums auf die Zusammensetzung der Darmmikrobiota bei Patienten mit bioptisch gesicherter nichtalkoholischer Fettlebererkrankung

10. Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation

14. Micafungin Twice Weekly as Antifungal Prophylaxis in Pediatric Patients at High Risk for Invasive Fungal Disease

16. Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis

18. Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis

27. Investigation of gut microbiota composition in humans carrying blastocystis subtypes 1 and 2 and Entamoeba hartmanni.

28. Antibiotics-Induced Intestinal Immunomodulation Attenuates Experimental Autoimmune Neuritis (EAN).

29. Torque teno virus-DNA load as individual cytomegalovirus risk assessment parameter upon allogeneic hematopoietic stem cell transplantation.

30. TIGIT + NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients.

31. The gut microbiome in intravenous immunoglobulin-treated chronic inflammatory demyelinating polyneuropathy.

32. Dietary omega-6/omega-3 ratio is not associated with gut microbiota composition and disease severity in patients with nonalcoholic fatty liver disease.

33. Longitudinal variability in the urinary microbiota of healthy premenopausal women and the relation to neighboring microbial communities: A pilot study.

34. Analysis of Human Gut Microbiota Composition Associated to the Presence of Commensal and Pathogen Microorganisms in Côte d'Ivoire.

35. Fecal microbiota transfer for refractory intestinal graft-versus-host disease - Experience from two German tertiary centers.

36. Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease.

37. A quality improvement study on the reduction of central venous catheter-associated bloodstream infections by use of self-disinfecting venous access caps (STERILE).

38. Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time?

39. Antibiotic Resistance and Mobile Genetic Elements in Extensively Drug-Resistant Klebsiella pneumoniae Sequence Type 147 Recovered from Germany.

40. Changes in the cervical microbiota of cervical cancer patients after primary radio-chemotherapy.

41. Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools.

42. High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD.

43. Potential biomarkers to predict outcome of faecal microbiota transfer for recurrent Clostridioides difficile infection.

44. Controlling intestinal colonization of high-risk haematology patients with ESBL-producing Enterobacteriaceae: a randomized, placebo-controlled, multicentre, Phase II trial (CLEAR).

45. Usability of rectal swabs for microbiome sampling in a cohort study of hematological and oncological patients.

46. Assessment of urinary 3-indoxyl sulfate as a marker for gut microbiota diversity and abundance of Clostridiales.

47. Fecal microbiota transplantation in a kidney transplant recipient with recurrent urinary tract infection.

48. Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children.

49. Low penetration of caspofungin into cerebrospinal fluid following intravenous administration of standard doses.

50. High Intracellular Concentrations of Posaconazole Do Not Impact on Functional Capacities of Human Polymorphonuclear Neutrophils and Monocyte-Derived Macrophages In Vitro.

Catalog

Books, media, physical & digital resources